These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 25428339

  • 1. Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer.
    Xue NZ, Fang RM, Lin LZ.
    Chin J Integr Med; 2014 Dec; 20(12):910-6. PubMed ID: 25428339
    [Abstract] [Full Text] [Related]

  • 2. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
    Zhou DH, Lin LZ, Zhou YQ, Luo RC, Liu KF, Jia YJ, Chen JY, Niu XW, Su BR, Lu J, Wang ST.
    Ai Zheng; 2005 Oct; 24(10):1252-6. PubMed ID: 16219143
    [Abstract] [Full Text] [Related]

  • 3. [Analysis of short-term therapeutic efficacy of integrated traditional and Western medicine in treating non-small cell lung cancer].
    Zhou DH, Lin LZ, Zhou YQ.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Dec; 25(12):1061-5. PubMed ID: 16398422
    [Abstract] [Full Text] [Related]

  • 4. [Effect of combination of syndrome differentiation depending treatment and chemotherapy on prognostic factors in treating mid-late patients with non-small call lung cancer].
    Li LN, Liu WS, Xu K.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Aug; 23(8):575-9. PubMed ID: 14503053
    [Abstract] [Full Text] [Related]

  • 5. Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study.
    Liu J, Lin HS, Hou W, Hua BJ, Zhang PT, Li J, Wang SY, Xie Y, Zhang Y, Xie GR, Zhang MY, Shi WG, Guan NB, Guan TY, Li CH, Lu LY, Zhang Y, Li DR, Liu H.
    Chin J Integr Med; 2017 Oct; 23(10):733-739. PubMed ID: 27796823
    [Abstract] [Full Text] [Related]

  • 6. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [Abstract] [Full Text] [Related]

  • 7. [Clinical Application of Immune-related Response Criteria in Evaluating Chinese Medical Treatme for Advanced Non-small Cell Lung Cancer].
    Jiang HW, Hu Q, He DF, Gao C, Yan YH, Ge LT.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Sep; 35(9):1074-7. PubMed ID: 26591362
    [Abstract] [Full Text] [Related]

  • 8. Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer.
    Xue D, Han S, Jiang S, Sun H, Chen Y, Li Y, Wang W, Feng Y, Wang K, Li P.
    Med Oncol; 2015 Apr; 32(4):114. PubMed ID: 25772512
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy].
    Zhang Y, Wang XQ, Liu H, Liu J, Hou W, Lin HS.
    Zhonghua Zhong Liu Za Zhi; 2018 Apr 23; 40(4):295-299. PubMed ID: 29730918
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y, Goto K.
    Lung Cancer; 2015 Dec 23; 90(3):477-83. PubMed ID: 26604031
    [Abstract] [Full Text] [Related]

  • 15. Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography.
    Knollmann FD, Kumthekar R, Fetzer D, Socinski MA.
    Clin Lung Cancer; 2014 Mar 23; 15(2):103-9. PubMed ID: 24361250
    [Abstract] [Full Text] [Related]

  • 16. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
    Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.
    Eur J Cancer; 2018 Jan 23; 88():38-47. PubMed ID: 29182990
    [Abstract] [Full Text] [Related]

  • 17. Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and Western medicine.
    Chen YZ, Feng XB, Li ZD, Zheng WX, Sun H, Li PP.
    Chin J Integr Med; 2014 Mar 23; 20(3):179-83. PubMed ID: 24615210
    [Abstract] [Full Text] [Related]

  • 18. [Effect of traditional Chinese medicine in improving quality of life of patients with non-small cell lung cancer in late stage].
    Lin LZ, Zhou DH, Zheng XT.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 May 23; 26(5):389-93. PubMed ID: 16883901
    [Abstract] [Full Text] [Related]

  • 19. The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.
    Zhou T, Zheng L, Hu Z, Zhang Y, Fang W, Zhao Y, Ge J, Zhao H, Zhang L.
    Sci Rep; 2015 Jan 08; 5():7683. PubMed ID: 25567662
    [Abstract] [Full Text] [Related]

  • 20. Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.
    Kataoka Y, Hirano K, Narabayashi T, Hara S, Fujimoto D, Tanaka T, Ebi N, Tomii K, Yoshioka H.
    Cancer Chemother Pharmacol; 2018 Feb 08; 81(2):333-337. PubMed ID: 29230503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.